Search

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide

Black innovators contribution to health & wellness throughout the years

Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.

Pioneers who inspire: Women in livestock

Biosimilars

Consumer Health Data Privacy

This Consumer Health Data Privacy Policy applies to “Consumer Health Data,” as that term has been defined under applicable law.

Supplier Diversity

FIBRONEER™ trials for IPF, other progressive fibrosing ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

FDA Grants Priority Review for Spesolimab | BI US

Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Meeting the Challenge in Animal Health

Video showing how Boehringer Ingelheim Animal Health is driving collaboration and innovation to Meet the Challenge in Animal Health.

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Boehringer Ingelheim wins 2023 Prix Galien USA

Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award

New consortium EUbOPEN will provide tools to unlock disease biolog

Express Scripts Adds BI Products to Roster | BI US

Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

Planting Trees to Help Care for the Environment

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Onboarding

Championing minds for generations both in and out of the workplace

Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.

Federal and State Laws

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.

Management Rotation | Academic Programs

Management Rotation Program

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers